Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Capital Expenditures (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Capital Expenditures for 6 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 21.99% year-over-year to $2.4 million, compared with a TTM value of $13.5 million through Dec 2025, up 16.6%, and an annual FY2025 reading of $13.5 million, up 16.6% over the prior year.
  • Capital Expenditures was $2.4 million for Q4 2025 at Treace Medical Concepts, down from $2.8 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $5.9 million in Q3 2022 and bottomed at $196000.0 in Q1 2021.
  • Average Capital Expenditures over 5 years is $2.7 million, with a median of $2.6 million recorded in 2025.
  • Peak annual rise in Capital Expenditures hit 1518.97% in 2021, while the deepest fall reached 70.92% in 2021.
  • Year by year, Capital Expenditures stood at $900000.0 in 2021, then surged by 159.11% to $2.3 million in 2022, then dropped by 3.6% to $2.2 million in 2023, then skyrocketed by 36.74% to $3.1 million in 2024, then decreased by 21.99% to $2.4 million in 2025.
  • Business Quant data shows Capital Expenditures for TMCI at $2.4 million in Q4 2025, $2.8 million in Q3 2025, and $4.8 million in Q2 2025.